Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureJazmin Reyes-Martinez, Erika Loredo-Calderon, Carlos A. Velázquez-Martínez
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Targeting of the FOXM1 oncoprotein by E3 ligase-assisted degradation
10.1021/acs.jmedchem.1c01069 · 2021
PROTAC targeted protein degraders: the past is prologue
10.1038/s41573-021-00371-6 · 2022
An overview of PROTACs: a promising drug discovery paradigm
10.1186/s43556-022-00112-0 · 2022
Critical assessment of targeted protein degradation as a research tool and pharmacological modality
10.1016/j.tips.2020.02.006 · 2020
PROTACs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
10.1073/pnas.141230798 · 2001
PROTACs: past, present and future
10.1039/d2cs00193d · 2022
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
2023
Critical parameters in targeted drug development: the pharmacological audit trail
10.1053/j.seminoncol.2016.06.001 · 2016
NDA submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders
10.1021/acs.jmedchem.5c01818 · 2025
Unresolved referenced work
Kept as external metadata until matched
Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential
10.1016/j.bcp.2025.117297 · 2025
Molecular glue degraders: rational design, specificity engineering, and advanced delivery
10.1016/j.apsb.2026.02.020 · 2026
Assays and technologies for developing proteolysis targeting chimera degraders
10.4155/fmc-2020-0073 · 2020
Binding affinity determination in drug design: insights from lock and key, induced fit, conformational selection, and inhibitor trapping models
10.3390/ijms25137124 · 2024
Insights into protein-ligand interactions: mechanisms, models, and methods
10.3390/ijms17020144 · 2016
DELs enable the development of BRET probes for target engagement studies in cells
10.1016/j.chembiol.2023.06.019 · 2023
Design, synthesis, and biological evaluation of small molecule PROTACs for potential anticancer effects
10.1007/s00044-019-02485-4 · 2019
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
10.7150/thno.75444 · 2022
Degradation of polo-like kinase 1 by the novel poly-arginine N-degron pathway PROTAC regulates tumor growth in nonsmall cell lung cancer
10.1021/acs.jmedchem.3c01493 · 2024
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
10.1016/j.apsb.2020.11.022 · 2021
Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression
10.1021/acs.jmedchem.8b00909 · 2019
Development of the first geldanamycin-based HSP90 degraders
10.3389/fchem.2023.1219883 · 2023
Discovery of a potent, cooperative, and selective SOS1 PROTAC ZZ151 with in vivo antitumor efficacy in KRAS-mutant cancers
10.1021/acs.jmedchem.3c00075 · 2023
Lessons in PROTAC design from selective degradation with a promiscuous warhead
10.1016/j.chembiol.2017.09.010 · 2018
PROTAC 2.0: expanding the frontiers of targeted protein degradation
10.1016/j.drudis.2025.104376 · 2025
Fluorescence polarization assays in small molecule screening
10.1517/17460441.2011.537322 · 2011
Fluorescence polarization: past, present and future
10.2174/138620703106298347 · 2003
Fluorescence polarization immunoassay: detection of antibody to Brucella abortus
10.1006/meth.2000.1038 · 2000
Plasticity in binding confers selectivity in ligand-induced protein degradation
10.1038/s41589-018-0055-y · 2018
Analysis of protein-ligand interactions by fluorescence polarization
10.1038/nprot.2011.305 · 2011
Surface plasmon resonance: towards an understanding of the mechanisms of biological molecular recognition
10.1016/s1367-5931(00)00251-9 · 2001
Discovery of the first potent DYRK2 proteolysis targeting chimera degraders
10.1021/acsmedchemlett.4c00065 · 2024
A novel strategy to block mitotic progression for targeted therapy
10.1016/j.ebiom.2019.10.013 · 2019
Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL-positive leukemia
10.1158/0008-5472.can-24-1093 · 2025
Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human cancer cells harboring various KRAS mutations
10.1021/acs.jmedchem.1c01774 · 2022
Discovery of precision targeting EZH2 degraders for triple-negative breast cancer
10.1016/j.ejmech.2022.114462 · 2022
Plasmonic nanoholes in a multichannel microarray format for parallel kinetic assays and differential sensing
10.1021/ac802276x · 2009
Real-time and label-free bio-sensing of molecular interactions by surface plasmon resonance: a laboratory medicine perspective
2012
Overcoming limitations of FRET measurements
10.1002/cyto.a.22851 · 2016
A substrate-independent TR-FRET histone deacetylase inhibitor assay
10.1177/1087057111422102 · 2011
Direct-to-biology accelerates PROTAC synthesis and the evaluation of linker effects on permeability and degradation
10.1021/acsmedchemlett.2c00124 · doi-reference
Proximity-based modalities for biology and medicine
10.1021/acscentsci.3c00395 · doi-reference
Development and validation of LC-MS/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide (ARV-110) and vepdegestrant (ARV-471)
10.1016/j.jpba.2024.116348 · doi-reference
PK/PD modeling of targeted protein degraders: charting new waters and navigating the shallows
10.1016/j.drudis.2025.104311 · doi-reference
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs
10.1038/s43856-024-00505-y · doi-reference
Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation
10.1039/d1cs00762a · doi-reference
Intraperitoneal route of drug administration: should it be used in experimental animal studies?
10.1007/s11095-019-2745-x · doi-reference
When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry—the red, brown, and blue technique
10.1177/0300985813505879 · doi-reference
Target validation using PROTACs: applying the four pillars framework
10.1177/2472555220979584 · doi-reference
Preclinical mouse cancer models: a maze of opportunities and challenges
10.1016/j.cell.2015.08.068 · doi-reference
A novel β-carboline alkaloid derivative targeting MDM2-p53 pathway suppresses colorectal cancer progression
10.1007/s13402-025-01111-3 · doi-reference
Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition
10.1186/s12885-025-14361-z · doi-reference
PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis
10.1038/s41419-019-2022-2 · doi-reference
Comparison of cytotoxicity evaluation of anticancer drugs between real-time cell analysis and CCK-8 method
10.1021/acsomega.9b01142 · doi-reference
In vitro cell death determination for drug discovery: a landscape review of real issues
10.1177/1179670717691251 · doi-reference
An overview of the current state of cell viability assessment methods using OECD classification
10.3390/ijms26010220 · doi-reference
Unlocking the potential of camel milk-derived exosomes as novel delivery systems: enhanced bioavailability of ARV-825 PROTAC for cancer therapy
10.3390/pharmaceutics16081070 · doi-reference
Methods to accelerate PROTAC drug discovery
10.1042/bcj20243018 · doi-reference
PROTACs: emerging targeted protein degradation approaches for advanced druggable strategies
10.3390/molecules28104014 · doi-reference
Targeting of Brahma-related gene-1 (BRG1) overcomes paclitaxel-induced multidrug resistance caused by overexpression of the subset of ATP-binding cassette (ABC) transporters
10.1016/j.jpet.2025.103772 · doi-reference
Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation
10.1080/14756366.2025.2468355 · doi-reference
Design, synthesis, and anticancer activity evaluation of the new SHP2 degraders
10.1002/slct.202405728 · doi-reference
Design, synthesis, and biological evaluation of RIPK1-targeting PROTACs
10.1007/s11030-025-11166-x · doi-reference
A platinated prodrug leveraging PROTAC technology for targeted protein degradation and enhanced antitumor efficacy
10.1039/d5qi00605h · doi-reference
Replacing a cereblon ligand by a DDB1 and CUL4 associated factor 11 (DCAF11) recruiter converts a selective histone deacetylase 6 PROTAC into a pan-degrader
10.1002/cmdc.202500035 · doi-reference
Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRWT and EGFRT790M
10.1080/14756366.2022.2062338 · doi-reference
Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
10.1186/s13046-022-02483-2 · doi-reference
Rational design and synthesis of HSF1-PROTACs for anticancer drug development
10.3390/molecules27051655 · doi-reference
Controlled bioorthogonal activation of Bromodomain-containing protein 4 degrader by co-delivery of PROTAC and Pd-catalyst for tumor-specific therapy
10.1016/j.jconrel.2024.08.032 · doi-reference
Targeting BET proteins with a PROTAC molecule elicits potent anticancer activity in HCC cells
10.3389/fonc.2019.01471 · doi-reference
Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia
10.1016/j.bioorg.2024.107319 · doi-reference
Hydroxamic acids immobilized on resins (HAIRs): synthesis of dual-targeting HDAC inhibitors and HDAC degraders (PROTACs)
10.1002/anie.202006725 · doi-reference
New thalidomide-resembling dicarboximides target ABC50 protein and show antileukemic and immunomodulatory activities
10.3390/biom9090446 · doi-reference
BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade
10.1038/s41388-021-02041-8 · doi-reference
Targeting CDK9 in cancer: an integrated approach of combining in silico screening with experimental validation for novel degraders
10.3390/cimb46030111 · doi-reference
Design, synthesis and biological evaluation of novel TMPRSS2-PROTACs with florosubstituted 4-guanidino-N-phenylbenzamide derivative ligands
10.1016/j.bmc.2024.117982 · doi-reference
Nanoformulation of PROteolysis TArgeting Chimera targeting ‘undruggable’ c-Myc for the treatment of pancreatic cancer
10.2217/nnm-2020-0156 · doi-reference
Discovery of the first examples of threonine tyrosine kinase PROTAC degraders
10.1021/acs.jmedchem.1c01768 · doi-reference
Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein
10.1016/j.bioorg.2021.104901 · doi-reference
Susceptibility of lung carcinoma cells to nanostructured lipid carrier of ARV-825, a BRD4 degrading proteolysis targeting chimera
10.1007/s11095-022-03184-3 · doi-reference